Our research aims to discover the mechanisms behind leukocyte trafficking, organ disease and tissue remodelling with the ultimate goal to develop novel therapeutic approaches. The latter would include small molecule agonists and antagonists, targeting and therapeutic antibodies, nutraceutical strategies to augment patient-specific pro-resolving pathways.
We have expanded our inflammation research impact with the formation of a cross-institute multi-faculty Centre for Inflammation and Therapeutic Innovation (CiTI) establishing a strategic partnership with Arthritis Research UK, UCB Pharma and UCL Partners. During the first phase of financing of CiTI, we have established two Arthritis Research UK Chairs at WHRI. CiTI harness WHRI inflammation research themes, and bring together other sections of the Faculty, with a focus on therapeutic innovation.
Genomic Medicine and Patient StratificationLead researchers: Pitzalis, Bombardieri, Lewis, Mageed, Dalli, Barnes, Mantovani, Montero-Melendez
Vascular InflammationLead researchers: Nourshargh, Rot, Marelli-Berg, Cooper, Voisin, Hobbs, Ahluwalia, Henson, Ackland, Longhi, Thiemermann, Nightingale, Solito
Therapeutic Innovation and PharmacologyLead researchers: Perretti, Mantovani, Marelli-Berg, Nissim, Dalli, Norling, Whiteford, Thiemermann, Yaqoob, Aksoy, Corsiero, Pitzalis, Rot, Chen, Montero-Melendez
Repair and Regenerative MedicineLead researchers: Dell’Accio, Perretti, Dalli, Norling, Eldridge, Montero-Melendez
As such our inflammation programme dovetails very well with a large proportion of our efforts in cardiovascular research.
Our translational research is published in Science and Nature journals, Immunity, PNAS, JCI and more, and the excellence of our research is recognised by the award of the Arthritis Research UK Early Arthritis Treatment Centre and an NIHR Translational Research Partnership as well as by high profile individual fellowships, training programmes and more.